PTEN: A default gate-keeping tumor suppressor with a versatile tail

Cell Research

Volumn 18, Issue 8, 2008, Pages 807-816

  Wang, Xinjiang ^a   Jiang, Xuejun ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

p53; Posttranslational regulation; PTEN; Tumor suppressor; Ubiquitination

Indexed keywords

NEDD4 UBIQUITIN PROTEIN LIGASES; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE;

ANIMAL; CELL TRANSFORMATION; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; PROTEIN PROCESSING; PROTEIN TERTIARY STRUCTURE; REVIEW; UBIQUITINATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

PYRONIA TITHONUS;

EID: 49149086504     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2008.83     Document Type: Review

References (87)

1. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943-1947.
2. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15:356-362.
3. Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997; 57:2124-2129.
4. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95:29-39.
5. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998; 19:348-355.
6. Sun H, Lesche R, Li DM, et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA 1999; 96:6199-6204.
7. Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999; 96:1563-1568.
8. Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 1999; 91:1922-1932.
9. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22:2954-2963.
10. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16:64-67.
11. Marsh DJ, Dahia PL, Zheng Z, et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 1997; 16:333-334.
12. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273:13375-13378.
13. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999; 96:4240-4245.
14. Tamura M, Gu J, Matsumoto K, et al. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998; 280:1614-1617.
15. Raftopoulou M, Etienne-Manneville S, Self A, Nicholls S, Hall A. Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science 2004; 303:1179-1181.
16. Gu J, Tamura M, Pankov R, et al. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol 1999; 146:389-403.
17. Mahimainathan L, Choudhury GG. Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J Biol Chem 2004; 279:15258-15268.
18. Myers MP, Pass I, Batty IH, et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 1998; 95:13513-13518.
19. Lee JO, Yang H, Georgescu MM, et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999; 99:323-334.
20. Gildea JJ, Herlevsen M, Harding MA, et al. PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. Oncogene 2004; 23:6788-6797.
21. Hlobilkova A, Guldberg P, Thullberg M, et al. Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity. Exp Cell Res 2000; 256:571-577.
22. Shen WH, Balajee AS, Wang J, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007; 128:157-170.
23. Zhou XP, Gimm O, Hampel H, et al. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 2000; 157:1123-1128.
24. Mirmohammadsadegh A, Marini A, Nambiar S, et al. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res 2006; 66:6546-6552.
25. Wiencke JK, Zheng S, Jelluma N, et al. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol 2007; 9:271-279.
26. Stambolic V, MacPherson D, Sas D, et al. Regulation of PTEN transcription by p53. Mol Cell 2001; 8:317-325.
27. Li Z, Dong X, Wang Z, et al. Regulation of PTEN by Rho small GTPases. Nat Cell Biol 2005; 7:399-404.
28. Martin-Belmonte F, Gassama A, Datta A, et al. PTEN-mediated apical segregation of phosphoinositides controls epithelial morphogenesis through Cdc42. Cell 2007; 128:383-397.
29. Gimm O, Perren A, Weng LP, et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 2000; 156:1693-1700.
30. Lachyankar MB, Sultana N, Schonhoff CM, et al. A role for nuclear PTEN in neuronal differentiation. J Neurosci 2000; 20:1404-1413.
31. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 2000; 20:5010-5018.
32. Okahara F, Ikawa H, Kanaho Y, Maehama T. Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein. J Biol Chem 2004; 279:45300-45303.
33. Valiente M, Andres-Pons A, Gomar B, et al. Binding of PTEN to specific PDZ domains contributes to PTEN protein stability and phosphorylation by microtubule-associated serine/threonine kinases. J Biol Chem 2005; 280:28936-28943.
34. Maccario H, Perera NM, Davidson L, Downes CP, Leslie NR. PTEN is destabilised by phosphorylation on threonine 366. Biochem J 2007; 405:439-444.
35. Kwon J, Lee SR, Yang KS, et al. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci USA 2004; 101:16419-16424.
36. Leslie NR, Bennett D, Lindsay YE, et al. Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J 2003; 22:5501-5510.
37. Connor KM, Subbaram S, Regan KJ, et al. Mitochondrial H2O2 regulates the angiogenic phenotype via PTEN oxidation. J Biol Chem 2005; 280:16916-16924.
38. Yu CX, Li S, Whorton AR. Redox regulation of PTEN by S-nitrosothiols. Mol Pharmacol 2005; 68:847-854.
39. Leslie NR. The redox regulation of PI 3-kinase-dependent signaling. Antioxid Redox Signal 2006; 8:1765-1774.
40. Tamguney T, Stokoe D. New insights into PTEN. J Cell Sci 2007; 120(Pt 23):4071-4079.
41. Gericke A, Munson M, Ross AH. Regulation of the PTEN phosphatase. Gene 2006; 374:1-9.
42. Campbell RB, Liu F, Ross AH. Allosteric activation of PTEN phosphatase by phosphatidylinositol 4,5-bisphosphate. J Biol Chem 2003; 278:33617-33620.
43. Tolkacheva T, Boddapati M, Sanfiz A, et al. Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer Res 2001; 61:4985-4989.
44. Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 2001; 276:993-998.
45. Adey NB, Huang L, Ormonde PA, et al. Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding. Cancer Res 2000; 60:35-37.
46. Wu X, Hepner K, Castelino-Prabhu S, et al. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci USA 2000; 97:4233-4238.
47. Hu Y, Li Z, Guo L, et al. MAGI-2 Inhibits cell migration and proliferation via PTEN in human hepatocarcinoma cells. Arch Biochem Biophys 2007; 467:1-9.
48. Wu W, Wang X, Zhang W, et al. Zinc-induced PTEN protein degradation through the proteasome pathway in human airway epithelial cells. J Biol Chem 2003; 278:28258-28263.
49. Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci USA 1999; 96:10182-10187.
50. Trotman LC, Niki M, Dotan ZA, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003; 1:E59.
51. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67:425-479.
52. Wang X, Trotman LC, Koppie T, et al. NEDD4-1 is a protooncogenic ubiquitin ligase for PTEN. Cell 2007; 128:129-139.
53. Ahn Y, Hwang CY, Lee SR, Kwon KS, Lee C. Tumor suppressor PTEN mediates a negative regulation of E3 ubiquitin-protein ligase Nedd4. Biochem J 2008; 412:331-338.
54. Trotman LC, Wang X, Alimonti A, et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 2007; 128:141-156.
55. Gil A, Andres-Pons A, Pulido R. Nuclear PTEN: a tale of many tails. Cell Death Differ 2007; 14:395-399.
56. Planchon SM, Waite KA, Eng C. The nuclear affairs of PTEN. J Cell Sci 2008; 121(Pt 3):249-253.
57. Wang X, Shi Y, Wang J, Huang G, Jiang X. The Crucial Role of the Carboxyl Terminus of PTEN in Antagonizing NEDD4-1-Mediated PTEN Ubiquitination and Degradation. Biochem J 2008 May 22. doi: 10.1042/BJ20080674
58. Anan T, Nagata Y, Koga H, et al. Human ubiquitin-protein ligase Nedd4: expression, subcellular localization and selective interaction with ubiquitin-conjugating enzymes. Genes Cells 1998; 3:751-763.
59. Hamilton MH, Tcherepanova I, Huibregtse JM, McDonnell DP. Nuclear import/export of hRPF1/Nedd4 regulates the ubiquitin-dependent degradation of its nuclear substrates. J Biol Chem 2001; 276:26324-26331.
60. Odriozola L, Singh G, Hoang T, Chan AM. Regulation of PTEN activity by its carboxyl-terminal autoinhibitory domain. J Biol Chem 2007; 282:23306-23315.
61. Simpson L, Parsons R. PTEN: life as a tumor suppressor. Exp Cell Res 2001; 264:29-41.
62. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000; 100:387-390.
63. Musatov S, Roberts J, Brooks AI, et al. Inhibition of neuronal phenotype by PTEN in PC12 cells. Proc Natl Acad Sci USA 2004; 101:3627-3631.
64. Puc J, Keniry M, Li HS, et al. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 2005; 7:193-204.
65. Sulis ML, Parsons R. PTEN: from pathology to biology. Trends Cell Biol 2003; 13:478-483.
66. Bonneau D, Longy M. Mutations of the human PTEN gene. Hum Mutat 2000; 16:109-122.
67. Eng C. PTEN: one gene, many syndromes. Hum Mutat 2003; 22:183-198.
68. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007; 170:1445-1453.
69. Zhou XP, Kuismanen S, Nystrom-Lahti M, Peltomaki P, Eng C. Distinct PTEN mutational spectra in hereditary non-polyposis colon cancer syndrome-related endometrial carcinomas compared to sporadic microsatellite unstable tumors. Hum Mol Genet 2002; 11:445-450.
70. Ali IU. Gatekeeper for endometrium: the PTEN tumor suppressor gene. J Natl Cancer Inst 2000; 92:861-863.
71. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000; 92:924-930.
72. Cairns P, Okami K, Halachmi S, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997; 57:4997-5000.
73. Li M, Brooks CL, Wu-Baer F, et al. Mono- versus poly-ubiquitination: differential control of p53 fate by Mdm2. Science 2003; 302:1972-1975.
74. Kwon CH, Zhu X, Zhang J, et al. Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat Genet 2001; 29:404-411.
75. Lozano G, Liu G. Mouse models dissect the role of p53 in cancer and development. Semin Cancer Biol 1998; 8:337-344.
76. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003; 10:431-442.
77. Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell 2006; 21:307-315.
78. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28:622-629.
79. Whang YE, Wu X, Suzuki H, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998; 95:5246-5250.
80. Freeman DJ, Li AG, Wei G, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 2003; 3:117-130.
81. Tang Y, Eng C. PTEN autoregulates its expression by stabilization of p53 in a phosphatase-independent manner. Cancer Res 2006; 66:736-742.
82. Li AG, Piluso LG, Cai X, et al. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell 2006; 23:575-587.
83. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436:725-730.
84. Zhang J, Grindley JC, Yin T, et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 2006; 441:518-522.
85. Yilmaz OH, Valdez R, Theisen BK, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006; 441:475-482.
86. Groszer M, Erickson R, Scripture-Adams DD, et al. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 2001; 294:2186-2189.
87. Groszer M, Erickson R, Scripture-Adams DD, et al. PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci USA 2006; 103:111-116.